Capivasertib

Capivasertib (brand name Truqap) is a targeted AKT inhibitor approved by the U.S. Food and Drug Administration and other agencies for treating specific advanced, HR-positive, HER2-negative breast cancers. Used with fulvestrant, it treats adults with PIK3CA/AKT1/PTEN alterations whose cancer progressed after endocrine therapy